Experience

Davis Polk advised ADC Therapeutics SA in connection with its entry into a facility agreement with Deerfield Partners, L.P., pursuant to which Deerfield agreed to extend senior secured…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Diageo Capital plc of $750 million aggregate principal amount of 1.375% fixed-rate notes due 2025, …

Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…

Davis Polk advised the joint lead managers in connection with a Rule 144A/Regulation S offering by the Emirate of Abu Dhabi of $2 billion aggregate principal amount of 2.500% notes due 2025…

Davis Polk advised the joint book-running managers in connection with a Rule 144A/Regulation S offering of $600 million aggregate principal amount of 3.395% senior notes due 2030 by…

Davis Polk advised the underwriters on an SEC-registered offering by Baidu, Inc. of its $600 million 3.075% notes due 2025 and $400 million 3.425% notes due 2030. Baidu, Inc. is a…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Equinor ASA of $1.25 billion aggregate principal amount of 2.875% fixed-rate notes…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of $900 million aggregate principal amount of 4.700% notes due 2027, $1…

Davis Polk advised the joint bookrunners on an offering of $750 million aggregate principal amount of 5.375% senior notes due 2025 and $750 million aggregate principal amount of 5.625%…

Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A…